Ichorion Therapeutics is a clinical stage biotechnology company specializing in the treatment of immune dysregulation. Their focus is on developing targeted therapies that address the LIGHT-signaling network, which plays a crucial role in immune regulation. The company's goal is to reduce the levels of LIGHT, an immunoregulatory cytokine, in order to mitigate immune dysregulation in various acute and chronic inflammatory disorders.

Led by a dedicated and experienced team, Ichorion Therapeutics is committed to teamwork, scientific excellence, and patient care. Their cross-functional team possesses extensive knowledge in disease pathology and the clinical development of innovative therapeutic targets. Their combined expertise in discovery, development, and regulatory approvals has resulted in the successful advancement of numerous therapeutic programs to commercialization.

With a strong pipeline of potential treatments, Ichorion Therapeutics is at the forefront of precision medicine and is dedicated to improving the lives of patients suffering from immune dysregulation